Depemokimab has already shown its potential as a therapy for severe asthma in two other phase 3 trials – SWIFT-1 and SWIFT-2 – and GSK is in the process of preparing regulatory filings for the ...

GSK stock is up 21.5% in six months, fueled by strong Specialty Medicines growth and a promising pipeline despite vaccine ...

GSK's new long-acting drug candidate for severe asthma, depemokimab, reduced the rate of severe attacks by 54% in a pair of phase 3 trials presented at the European Respiratory Society ...

The severe asthma treatment market is experiencing robust expansion, driven by rising disease prevalence, improved diagnostic approaches, and breakthrough therapeutic developments from key ...

Depemokimab targets interleukin-5 (IL-5), which plays a crucial role in type 2 inflammation. GSK’s submission is supported by the positive Phase III SWIFT and ANCHOR trial data.

GSK also expects a regulatory decision on depemokimab in December and further pipeline entries such as efimosfermin. Despite the re-rating, GSK shares continue to trade at a discount. Specifically, it ...

Investing.com -- Berenberg has lowered its rating on GSK plc (LON:GSK) to Hold from Buy, a move driven by the stock’s strong year-to-date (YTD) performance and an expected pause in investor ...

GSK also expects a regulatory decision on depemokimab in December and further pipeline entries such as efimosfermin. Despite the re-rating, GSK shares continue to trade at a discount.

GSK also expects a regulatory decision on depemokimab in December and further pipeline entries such as efimosfermin. Despite the re-rating, GSK shares continue to trade at a discount. Specifically, it ...

The late-phase efficacy of benralizumab, depemokimab, and vilobelimab indicate reductions in disease activity and steroid dependence. As newer biologics get ready for approval, ...

GSK also expects a regulatory decision on depemokimab in December and further pipeline entries such as efimosfermin. Despite the re-rating, GSK shares continue to trade at a discount. Specifically, it ...